Descrizione del progetto
Porre fine al ritardo nella diagnosi dell’endometriosi
Una delle malattie croniche più comuni nelle donne fertili è l’endometriosi, che colpisce 14 milioni di donne nell’UE. La malattia è causata da una crescita di tessuto uterino principalmente nella parte inferiore dell’addome. I sintomi più comuni sono un dolore intenso durante le mestruazioni e il rapporto sessuale, nonché dolore pelvico cronico. Tuttavia, sono necessari anni perché la malattia venga diagnosticata correttamente e le donne che ne soffrono sono più esposte al rischio di cancro alle ovaie rispetto al resto della popolazione femminile. Il progetto TRENDO, finanziato dall’UE, affronterà i problemi principali nella diagnosi e nella terapia dell’endometriosi. Unendo esperti di scienza clinica e traslazionale e partner industriali provenienti da sei paesi europei e sudamericani, il progetto svilupperà biomarcatori e test non invasivi, che accorceranno il ritardo diagnostico e ridurranno l’accesso impari a un’assistenza sanitaria costosa.
Obiettivo
Endometriosis is a sever disease affecting 10% of reproductive age women, characterized by the presence of endometrial-like tissue outside of uterus. Due to the associated pain, inertility and a small, but increased risk for developing ovarian cancer, its socioeconomic impacts are considerable, and have a profound effect on women’s mental and physical health. Endometriosis is characterized by a diagnostic delay of a decade, as its diagnosis is surgery-based, and all attempts to identify the non-invasive biomarkers have not been progressed beyond the discovery. Moreover, current treatments include only surgery or hormonal medications with significant side effects. In view of the above, the endometriosis care is challenging, and is hampered by the considerable heterogeneity of clinical manifestations. TRENDO consortium addresses the main problems in endometriosis diagnosis and therapy in a multidisciplinary and trans-sectoral effort, bringing together the clinical and translational science experts, and industry partners from six European and South American countries. We develop non-invasive biomarkers and testing, which shorten the diagnostic delay, and reduce the unequal access to expensive healthcare. These biomarkers are tested for the suitability as drug targets, to monitor treatment response, and to predict the personalized clinical recommendations. By combining the strengths of our partners, we provide novel tools addressing the most urgent priorities in endometriosis and to successfully translate our findings into novel therapeutic approaches. This challenging scientific task provides an ideal career-enhancing setting for young scientists, providing them with transdisciplinary and trans-domain training, and with essential transferable skills. The training program provides a new generation of researchers with a strong competitive advantage on the job market and increase European academic and industry competence in one of the under-investigated clinical domains.
Campo scientifico
Parole chiave
Programma(i)
Meccanismo di finanziamento
MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)Coordinatore
48149 MUENSTER
Germania